Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Cash & Current Investments (2024 - 2025)

Prelude Therapeutics' Cash & Current Investments history spans 2 years, with the latest figure at $103.2 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 22.75% year-over-year to $103.2 million; the TTM value through Dec 2025 reached $103.2 million, down 22.75%, while the annual FY2025 figure was $103.2 million, 22.75% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $103.2 million at Prelude Therapeutics, up from $58.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $206.0 million in Q1 2024 and bottomed at $58.2 million in Q3 2025.